- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Cohance Lifesciences' Hyderabad Finished Dosage Formulations (FDF) plant underwent a USFDA Good Manufacturing Practices (GMP) inspection. The company received a Form 483 with 6 observations, which are predominantly procedural. Cohance Lifesciences is reviewing these findings and preparing a comprehensive response. The company reiterated its commitment to maintaining high quality standards and regulatory compliance for its global pharmaceutical products. This update signals a standard regulatory process, with the procedural nature of observations being a key point for investors.